How India Exports Trimethoprim to the World

In the United States, trimethoprim is approved for various indications, including urinary tract infections and certain respiratory infections. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for trimethoprim, indicating a competitive generic market. Notably, there have been recent approvals, such as [specific approval details with dates].

Regarding import alerts, as of March 2026, there are no specific FDA import alerts targeting trimethoprim from India. However, manufacturers must ensure compliance with FDA regulations to avoid potential detentions. The FDA's Import Alert 66-66, issued in October 2024, emphasizes the importance of proper labeling for active pharmaceutical ingredients (APIs) to prevent misbranding under section 502(f)(1) of the FD&C Act.

Given the presence of 278 active Indian exporters, maintaining stringent quality control and regulatory compliance is crucial to sustain market access and competitiveness in the U.S.

In the European Union, trimethoprim is subject to marketing authorization requirements overseen by the European Medicines Agency (EMA). A notable regulatory action includes the Periodic Safety Update Report Single Assessment (PSUSA) for trimethoprim, concluded in November 2025, which resulted in variations to the product information to enhance safety and efficacy. (ema.europa.eu)

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) continues to align with EU standards post-Brexit, requiring similar marketing authorizations and adherence to Good Manufacturing Practice (GMP) guidelines.

Trimethoprim is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The 22nd edition, published in September 2021, lists trimethoprim for the treatment of lower urinary tract infections. (iris.who.int)

Manufacturers must ensure that trimethoprim formulations comply with international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to meet quality and safety requirements across different markets.

In India, trimethoprim is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, trimethoprim is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics.

For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products. While trimethoprim is not currently subject to export restrictions, exporters should stay informed about regulatory changes that may impact export requirements.

Trimethoprim's primary patents have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive landscape necessitates adherence to stringent quality standards and regulatory compliance to maintain market share.

In November 2025, the EMA concluded a PSUSA for trimethoprim, resulting in updates to product information to enhance safety and efficacy. (ema.europa.eu)

In October 2024, the FDA issued Import Alert 66-66, focusing on APIs that appear to be misbranded due to labeling deficiencies. This alert underscores the importance of compliance with labeling requirements to avoid import detentions.

In September 2021, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of trimethoprim for treating lower urinary tract infections, highlighting its continued relevance in global health. (iris.who.int)

These developments emphasize the need for manufacturers and exporters to stay abreast of regulatory changes and ensure compliance to maintain market access and competitiveness.

India's pharmaceutical industry, including the production of Trimethoprim, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of India's APIs and KSMs are sourced from China, making the supply chain vulnerable to disruptions. This dependency exposes the industry to risks such as geopolitical tensions, trade restrictions, and environmental regulations affecting Chinese manufacturing.

In response, the Indian government has initiated the Production Linked Incentive (PLI) scheme to bolster domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme, aiming to reduce import dependence by half for critical pharmaceutical ingredients. While these efforts are promising, the transition to self-sufficiency is gradual, and the industry remains susceptible to external supply chain shocks in the interim.

Our proprietary trade data indicates that the top five exporters of Trimethoprim from India account for 45.4% of total exports, with MICRO LABS LIMITED alone contributing 28.4%. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges.

The PLI scheme, launched in 2020, aims to diversify and strengthen the supplier base by incentivizing domestic production of APIs and KSMs. However, as of March 2026, the scheme's impact on reducing supplier concentration in the Trimethoprim market remains limited, necessitating continued monitoring and strategic planning to mitigate single-source risks.

Recent geopolitical events have significantly impacted global supply chains. In February 2026, the closure of the Strait of Hormuz due to escalating conflicts disrupted the transportation of essential goods, including pharmaceuticals. This blockade led to increased shipping times and costs, affecting the timely delivery of Trimethoprim exports from India.

Additionally, tensions in the Red Sea region have further complicated shipping routes. Attacks on vessels have prompted rerouting, adding delays and escalating freight costs. (pharmasource.global) These disruptions underscore the vulnerability of pharmaceutical supply chains to geopolitical instability, emphasizing the need for robust risk mitigation strategies.

• Diversify Supplier Base: Encourage partnerships with multiple API and KSM suppliers, both domestically and internationally, to reduce reliance on a single source.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme and similar initiatives to strengthen local manufacturing capabilities for critical pharmaceutical ingredients.

• Develop Alternative Shipping Routes: Invest in logistics infrastructure that offers alternative pathways to mitigate the impact of regional conflicts on shipping lanes.

• Establish Strategic Reserves: Maintain buffer stocks of essential APIs and KSMs to cushion against supply chain disruptions.

• Implement Robust Monitoring Systems: Utilize advanced analytics to monitor geopolitical developments and supply chain performance, enabling proactive risk management.

RISK_LEVEL: MEDIUM